Reweighting Oranges to Apples: Transported RE-LY Trial Versus Nonexperimental Effect Estimates of Anticoagulation in Atrial Fibrillation

被引:12
作者
Webster-Clark, Michael [1 ]
Lund, Jennifer L. [1 ]
Sturmer, Til [1 ]
Poole, Charles [1 ]
Simpson, Ross J. [2 ]
Edwards, Jessie K. [1 ]
机构
[1] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27515 USA
[2] Univ N Carolina, Dept Med, Chapel Hill, NC 27515 USA
基金
美国国家卫生研究院;
关键词
Anticoagulation; Generalizability; Medicare; Older adults; Transportability; CLINICAL-TRIALS; ORAL ANTICOAGULANTS; STROKE PREVENTION; ADVERSE EVENTS; WARFARIN; DABIGATRAN; RIVAROXABAN; APIXABAN; OUTCOMES; THERAPY;
D O I
10.1097/EDE.0000000000001230
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Results from trials and nonexperimental studies are often directly compared, with little attention paid to differences between study populations. When target and trial population data are available, accounting for these differences through transporting trial results to target populations of interest provides useful perspective. We aimed to compare two-year risk differences (RDs) for ischemic stroke, mortality, and gastrointestinal bleeding in older adults with atrial fibrillation initiating dabigatran and warfarin when using trial transport methods versus nonexperimental methods. Methods: We identified Medicare beneficiaries who initiated warfarin or dabigatran from a 20% nationwide sample. To transport treatment effects observed in the randomized evaluation of long-term anticoagulation trial, we applied inverse odds weights to standardize estimates to two Medicare target populations of interest, initiators of: (1) dabigatran and (2) warfarin. Separately, we conducted a nonexperimental study in the Medicare populations using standardized morbidity ratio weighting to control measured confounding. Results: Comparing dabigatran to warfarin, estimated two-year RDs for ischemic stroke were similar with trial transport and nonexperimental methods. However, two-year mortality RDs were closer to the null when using trial transport versus nonexperimental methods for the dabigatran target population (transported RD: -0.57%; nonexperimental RD: -1.9%). Estimated gastrointestinal bleeding RDs from trial transport (dabigatran initiator RD: 1.8%; warfarin initiator RD: 1.9%) appeared more harmful than nonexperimental results (dabigatran initiator RD: 0.14%; warfarin initiator RD: 0.57%). Conclusions: Differences in study populations can and should be considered quantitatively to ensure results are relevant to populations of interest, particularly when comparing trial with nonexperimental findings. See video abstract:.
引用
收藏
页码:605 / 613
页数:9
相关论文
共 56 条
  • [1] Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples
    Austin, Peter C.
    [J]. STATISTICS IN MEDICINE, 2009, 28 (25) : 3083 - 3107
  • [2] Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: A modelling analysis based on a nationwide cohort study
    Banerjee, Amitava
    Lane, Deirdre A.
    Torp-Pedersen, Christian
    Lip, Gregory Y. H.
    [J]. THROMBOSIS AND HAEMOSTASIS, 2012, 107 (03) : 584 - 589
  • [3] Bareinboim E, 2013, ADV NEURAL INFORM PR, P136
  • [4] Improving Depression Among HIV-Infected Adults: Transporting the Effect of a Depression Treatment Intervention to Routine Care
    Bengtson, Angela M.
    Pence, Brian W.
    Gaynes, Bradley N.
    Quinlivan, E. Byrd
    Heine, Amy D.
    O'Donnell, Julie K.
    Crane, Heidi M.
    Mathews, W. Christopher
    Moore, Richard D.
    Westreich, Daniel
    O'Cleirigh, Conall
    Christopoulos, Katerina
    Mimiaga, Matthew J.
    Mugavero, Michael J.
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2016, 73 (04) : 482 - 488
  • [5] Borgan O., 2005, Encyclopedia of Biostatistics, V2
  • [6] Inverse probability-of-censoring weights for the correction of time-varying noncompliance in the effect of randomized highly active antiretroviral therapy on incident AIDS or death
    Cain, Lauren E.
    Cole, Stephen R.
    [J]. STATISTICS IN MEDICINE, 2009, 28 (12) : 1725 - 1738
  • [7] Generalizing Evidence From Randomized Clinical Trials to Target Populations
    Cole, Stephen R.
    Stuart, Elizabeth A.
    [J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 2010, 172 (01) : 107 - 115
  • [8] Dabigatran versus Warfarin in Patients with Atrial Fibrillation.
    Connolly, Stuart J.
    Ezekowitz, Michael D.
    Yusuf, Salim
    Eikelboom, John
    Oldgren, Jonas
    Parekh, Amit
    Pogue, Janice
    Reilly, Paul A.
    Themeles, Ellison
    Varrone, Jeanne
    Wang, Susan
    Alings, Marco
    Xavier, Denis
    Zhu, Jun
    Diaz, Rafael
    Lewis, Basil S.
    Darius, Harald
    Diener, Hans-Christoph
    Joyner, Campbell D.
    Wallentin, Lars
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (12) : 1139 - 1151
  • [9] On the Relation Between G-formula and Inverse Probability Weighting Estimators for Generalizing Trial Results
    Dahabreh, Issa J.
    Robertson, Sarah E.
    Hernan, Miguel A.
    [J]. EPIDEMIOLOGY, 2019, 30 (06) : 807 - 812
  • [10] Extending inferences from a randomized trial to a target population
    Dahabreh, Issa J.
    Hernan, Miguel A.
    [J]. EUROPEAN JOURNAL OF EPIDEMIOLOGY, 2019, 34 (08) : 719 - 722